The label for Nurtec ODT (rimegepant) underwent a revision to its Indications and Usage section, effective 2026-06-04. This update clarifies that Nurtec ODT is indicated for both the acute treatment of migraine with or without aura in adults and the preventive treatment of episodic migraine in adults.
Background
Nurtec ODT (rimegepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist, a class of medications that target the CGRP pathway involved in migraine pathophysiology. It is used in the management of migraine, a complex neurological condition characterized by severe headaches, often accompanied by debilitating symptoms such as throbbing pain, sensitivity to light and sound (photophobia and phonophobia), and nausea or vomiting. Migraine attacks can significantly impact an individual's daily life and overall quality of life, leading to substantial disability. Treatments like rimegepant aim to either rapidly alleviate the symptoms of an acute migraine attack or reduce the frequency of migraine episodes in those with episodic migraine.
What this means
The updated label for Nurtec ODT provides clear and concise language regarding its established indications, reinforcing its role as a versatile therapeutic option for migraine management. This revision ensures that healthcare providers have the most current and accurate information when considering rimegepant for their patients. Clinicians can confidently continue to prescribe Nurtec ODT for the acute treatment of migraine with or without aura in adults, addressing the immediate pain and associated symptoms of an attack. Furthermore, the label explicitly supports its use for the preventive treatment of episodic migraine in adults, offering a strategy to reduce the frequency of future migraine episodes. This clarity in labeling is crucial for informed prescribing decisions and patient education.
Source
The information regarding this label revision was sourced from the FDA, specifically from the DailyMed database. The updated Indications and Usage section for NURTEC ODT (rimegepant) became effective on 2026-06-04, and is accessible via dailymed.nlm.nih.gov.